Celularity Forum: Community User: Ayur_Vader

https://celularity.com/celularity-announces-1-for-10-reverse-stock-split/

https://finance.yahoo.com/news/celularity-inc-nasdaq-celu-top-101534723.html

https://celularity.com/celularitys-tri-layer-decellularized-dehydrated-human-amniotic-membrane-product-investigated-as-a-carrier-of-induced-pluripotent-stem-cell-derived-limbal-stem-cells-in-the-treatment-of-sever/

https://www.marketbeat.com/instant-alerts/nasdaq-celu-options-data-report-2024-02-13/

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celu/celularity/news/celularity-inc-nasdaqcelu-held-back-by-insufficient-growth-e

https://celularity.com/celularity-announces-net-sales-expectations-for-first-quarter-2024-and-full-year-2024-reiterates-advanced-biomaterial-product-commercial-and-development-pipeline/

FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company), a biotechnology company developing allogeneic cell therapies and biomaterial products, today announced that it closed two financing transactions totaling $21 million in gross proceed. As detailed in the Form 8-K filed by the Company, one of the two financing transactions is a securities purchase agreement with the Company’s largest investor, Dragasac Limited (“Dragasac”) providing for the private placement of shares of Celularity Class A common stock and accompanying warrants for an aggregate purchase price of approximately $6 million. The other financing transaction is an agreement amending and restating the Company’s previously announced senior secured loan agreement with Resorts World Inc Pte Ltd. (“RWI”) for an additional loan of $15.0 million. Both the Dragasac private placement and the RWI senior secured loan agreement closed on January 16, 2024. According to Robert J. Hariri, M.D., Ph.D., Chairman, Chief Executive Officer, and founder, “These transactions are important in two fundamental ways. First, both Dragasac and RWI increased their existing financial stakes in Celularity, Dragasac through the $6 million private placement and RWI through the $15 million amended and restated senior secured loan. Second, the transactions together infused $21 million of fresh capital into Celularity, which we will apply to strengthen our balance sheet and for other purposes. Importantly, this capital infusion allowed us last week to repay in full all outstanding amounts owed to Yorkville under the September 15, 2022, YA II PN, Ltd. pre-paid advance agreement. We aligned with Dragasac and RWI around other uses intended further to strengthen our balance sheet and provide working capital. Along with revenue from our advanced biomaterial products and biobanking businesses, contract manufacturing operations, and cell therapy research collaborations, I believe the $21 million in new capital from these financing transactions has repositioned Celularity financially going into what I am optimistic will be a positive year in 2024,” Hariri added. Tan Sri Lim Kok Thay, Chairman and Chief Executive of Genting Berhad, the parent company of Dragasac, commented, “We believe Celularity’s platform businesses in cellular medicine, advanced biomaterial products, and biobanking each have significant growth opportunities, both in the United States as well as in Asia, where there is a large and rapidly growing market for regenerative medicine. Having now improved Celularity’s balance sheet and provided additional working capital, we look for Celularity in 2024 to concentrate on growing its operating revenue and to capitalize on opportunities like those we see in the United States and Asia.”

Our cell therapy platform includes clinical- and development-stage, off-the-shelf allogeneic cell therapy candidates, some of these employ mechanisms such as recognition of expressed stress antigens thought to potentially target aging processes which contribute to many degenerative disorders and diseases. It is increasingly recognized that the emerging longevity market represents one of the most exciting opportunities in the next decade. Recently, I addressed the HLTH 2023 conference as part of a panel focused on “moonshot thinking” about emergent technologies, treatments, and discoveries to create a healthier future. This aligns with the mission to democratize regenerative medicine that I discussed in the book I coauthored with Tony Robbins and Peter Diamandis and which has been a Celularity lodestar since inception. I believe Celularity’s clinical-stage assets in cell therapy and advanced biomaterials, including placental NK cells, placental pluripotent stem cells and biomaterials like Interfyl can play a role in age-related diseases. Obviously, there is work to be done but the scalability and affordability inherent to our use of the postpartum placenta as a source of newborn cells and biomaterials is what we believe positions Celularity as a regenerative medicine innovator in the emerging science of aging and longevity. I want to stress, our work over the last decade has focused on the biology of placental cells and I believe this has taught us that many of the mechanisms responsible for cancer, serious immunological and degenerative diseases have common denominators which may be addressed with our technology. By one estimate the longevity and anti-senescence therapy market was valued at $26.12 billion in 2022 and is predicted to reach $44.92 billion by the year 2031, growing at a 6.8% CAGR during the forecast period. There is no doubt, the last two years have been particularly challenging for companies in biotechnology and cell therapy specifically. As you have all witnessed, Celularity has struggled to keep Celularity operating through this period and our valuation has been severely impacted by market conditions. As you all know, I have personally continued to invest heavily in Celularity because my commitment is unwavering. However, I believe our ability to continue our work, build our revenues, and manage our finances with the loyal support of our long-term investors will help navigate 2024. I deeply appreciate each of you who, like me, have maintained your belief in Celularity’s fundamental value proposition despite recent choppy waters for the biotechnology sector as a whole. Thanks to each of you for your continued support and I look forward to providing future updates about our progress. Sincerely, Robert J. Hariri, M.D., Ph.D. Chairman, CEO and Founder

FLORHAM PARK, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, which is included below and can also be accessed here. Dear Shareholders, I would like to wish everyone belated greetings for the new year as I take a moment and share some personal thoughts for the year ahead. Celularity as you know is a novel combination of two commercial-stage, revenue-producing businesses — one manufacturing and selling advanced biomaterial products and the other providing specialized biobanking services — and a clinical-stage cellular medicine business focused on the treatment of immunological and degenerative disorders as well as diseases associated with aging. All three businesses leverage a common technology platform that we built around the postpartum placenta and the international patent estate developed over the course of two decades. Within the last few weeks, we announced net sales expectations for the fourth quarter 2023 and the full year 2023, respectively. As disclosed in that announcement, we expect our advanced biomaterial products and biobanking businesses to achieve net sales percentage growth in the range of 176.1% to 193.0% for the fourth quarter 2023 compared to the fourth quarter 2022. For the full year 2023, we expect net sales percentage growth in the range of 22.7% to 26.6% compared to the full year 2022. We anticipate shortly that we will announce our expectations for net sales in the first quarter 2024 and the full year 2024, respectively, reflecting three core focuses: First, maintain and build the sales momentum we achieved in the fourth quarter 2023, for which we expect to report triple-digit percentage growth in net sales by our advanced biomaterial products and biobanking businesses. Second, advance novel product candidates to meet market demand like we did with the introduction of Biovance®3L, which led our fourth quarter 2023 triple-digit percentage net sales growth. Third, expand opportunistically outside our core wound care and surgical applications like, for example, the commercialization agreement we announced early this month around dental and oral healthcare applications in periodontology, implant dentistry, and oral surgery. We are laser focused on opportunities to grow revenue from the sale of our advanced biomaterial products and biobanking services, with a goal of moving over time to being a cashflow positive enterprise. Recently, we took steps to improve our balance sheet and support the growth of our businesses. On Wednesday, 17 January, we announced the closing of two separate financing transactions in which Celularity received combined total gross proceeds of $21 million from a $6 million private placement transaction with our largest single shareholder and a $15 million loan agreement amendment with an existing lender, respectively. Celularity entered 2024 deeply engaged in the launch of the multi-year Research Collaboration Services Agreement in cell therapy with Regeneron Pharmaceuticals, Inc., which we announced in August. As previously disclosed, the collaboration’s initial focus is research on a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron, which is designed to enhance proliferation and potency against solid tumors. This important work will take place at Celularity’s Florham Park headquarters, which incorporates state-of-the-art research and manufacturing infrastructure. I see the Regeneron collaboration as an important validator of our cell therapy expertise, technical infrastructure, and capabilities as well as, I believe, potentially paving the way for future industry collaborations.

FLORHAM PARK, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications. A copy of BioCellgraft’s announcement of the agreement can be accessed here: https://www.prweb.com/releases/biocellgraft-finalizes-commercialization-agreement-with-celularity-for-the-manufacture-and-distribution-of-products-for-therapeutic-use-in-oral-healthcare-302025082.html. Robert J. Hariri, M.D., Ph.D., Chairman, Chief Executive Officer, and founder of Celularity, said, “This commercialization agreement with BioCellgraft opens an important pathway for Celularity-manufactured, BioCellgraft-branded and marketed advanced biomaterial products into dental and oral healthcare applications in the United States that include periodontology, implant dentistry and oral surgery, all of which are large and growing markets.”

FLORHAM PARK, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company), a biotechnology company developing allogeneic cell therapies and biomaterial products, today announced expected net sales of its advance biomaterial products and biobanking businesses for the fourth quarter 2023 and the full year 2023 and expected total revenue for the fourth quarter 2023 and the full year 2023. For the fourth quarter 2023, the Company expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million and the net sales percentage growth to be in the range of 176.1% to 193.0% compared to the fourth quarter 2022. For the full year 2023, the Company expects net sales of its biomaterial products and biobanking businesses to be in the range of $22.06 million to $22.76 million and the net sales percentage growth to be in the range of 22.7% to 26.6% compared to the full year 2022. The Company anticipates that it will announce actual net sales and actual total revenue for the fourth quarter of 2023 and the full year of 2023 later this year. “We are particularly encouraged by the growth in net revenues from our commercial-stage products and services as a testament to our unique business model, which produces both cellular and regenerative tools for several clinical indications such as wound healing and orthopedics. Considering the financial challenges experienced in the cellular medicine sector in 2023, the Company is working to maximize access to capital through cash flow from our manufactured biomaterial products, technical operations expertise, and cell banking activities. Based on the growth of this part of our business, we anticipate being able to provide revenue guidance across our entire business for 2024 in the very near future,” said Robert J. Hariri, M.D., Ph.D., Chairman, Chief Executive Officer, and founder.

Celularity CEO acquires stock worth ~$3M Oct. 11, 2023 8:30 AM ETCelularity Inc. (CELU)SRNE Celularity (NASDAQ:CELU) CEO Robert Hariri acquired stock worth ~$3M in the biotechnology company as part of a shares repurchase agreement with Sorrento Therapeutics (OTCPK:SRNEQ). CELU shares were trading 12.12% higher Wednesday pre-market. Hariri bought 9.06M class A shares for $0.1655; 6.31M shares for $0.1586 and 3.05M shares for $0.1586. The shares were purchased from Sorrento Therapeutics. Sorrento Therapeutics had filed for Chapter 11 bankruptcy in a Texas bankruptcy court in February. The director and 10% owner now owns 28.57M shares of direct holding in the company. In the last 3 months, CELU has seen 1 open market buy transaction with 875,000 shares acquired, and 2 sell transactions with 15,371,697 shares sold.

FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc. (Regeneron) to support the research of Regeneron’s allogeneic cell therapy candidates. The agreement’s initial focus is the research on a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. The research will take place at Celularity’s state-of-the-art facility located in Florham Park, N.J. Financial terms were not disclosed. “The agreement with Regeneron announced today is an important milestone for Celularity that recognizes our expertise in the research of cellular therapies, including the engineering of CAR-T cells. We believe that this relationship paves the way for future industry collaborations leveraging our world class cell therapy facilities and capabilities,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder. “We have long admired the exceptional scientific legacy at Regeneron and welcome the opportunity to collaborate with a world leader in innovative medicines.”

👍

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

We presented biomaterial data at the 7th International Conference on Orthopedics from an in vitro study of decellularized-flowable placental connective tissue matrix supporting cellular functions of human tenocytes. Our scientists also presented data at the International Conference on Biomaterials Science and Tissue Engineering in Osaka, Japan, that support our belief that Celularity’s unique proprietary processes result in human placental-derived biomaterial products that demonstrate superior biocompatibility and better support differentiated cell functions, as compared with other human placental-derived biomaterials which may contain cellular residuals. Staying with biomaterials, our pipeline includes two investigational-stage products that we are developing as devices regulated by the FDA’s Center for Devices and Radiological Health (CDRH). Our FUSE Bone Void Filler (“FUSE”) is being developed for use as a passive osteoconductive bone filler in the pelvis, extremities, and posterior-lateral spinal fusion settings as well as other skeletal defects. We intend to submit a 510(k) notification for FUSE in early 2024. In addition, we are developing our Celularity Tendon Wrap (CTW) for use as a surgical mesh for the management and protection of tendon injuries and intend to submit a 510(k) application by the end of 2023. Last week, we raised approximately $3.0 million of additional working capital intended to help bridge the company through some of the events discussed above, including shipping product for distribution in the Middle East. While navigating capital markets is challenging, we remain confident in our ability to do so in a manner that is prudent and consistent with long-term value. This is an exciting time during which Celularity continues to gather critical momentum. As we work through the challenges we face in today’s environment, we remain focused on both the long-term potential of our programs and products to bring forward innovative solutions to patients in need, and our commitment to creating meaningful sustainable shareholder value. I thank you for your continued support. I will continue to keep you informed of our progress. Sincerely, Robert J. Hariri, M.D., Ph.D. Chairman, CEO and Founder